Overview

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Status:
Recruiting

Trial end date:
2024-02-12

Target enrollment:

Participant gender:

Summary

This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Osimertinib